ResMed Inc. stock dips as CEO share sale draws investor attention

Published on 09/10/2026 at 19:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

ResMed Inc. stock closed at USD 221.05 on September 9, 2026, down 3.3 percent on the NYSE as insider selling by CEO Michael Farrell made headlines. The Q4 FY26 revenue of USD 1.46 billion and profit margin above 26 percent underline that fundamentals remain solid.

Schwarzweiß-Reportagefoto eines Patienten mit Atemmaske im Schlaflabor — ResMed Inc. (ISIN US7611521078): dokumentarische Schwarzweiß-Reportage zeigt einen Patienten mit Atemmaske im Schlaflabor, Illustration mit AI erstellt.

ResMed Inc. stock (ISIN US7611521078) closed at USD 221.05 on the NYSE on September 9, 2026, down 3.3 percent from the prior close in a session that saw the shares trade between USD 220.45 and USD 226.67, per NYSE data reported by MarketWatch.

CEO share sale becomes the near-term catalyst

Investor attention on September 10, 2026 centers on insider activity after CEO Michael Farrell sold 4,991 ResMed shares at an average price of about USD 222.44 per share, for a total transaction value of roughly USD 1.11 million, according to MarketBeat on September 10, 2026.

The same trading activity is described in more detail in a filing-based report noting that the 4,991 shares were sold at a weighted average price of USD 222.44 per share, with individual trades executed between about USD 220.68 and USD 225.39, while options for an equal number of shares were exercised at USD 146.34 per share, as Investing.com reports on September 10, 2026.

Recent price action and valuation context

On September 10, 2026, ResMed stock was quoted around USD 219.52 on the NYSE, about 0.69 percent below the last close, with a previous close of USD 221.05 and an open of USD 220.85, according to data shown by Yahoo Finance.

The same overview places the 52-week high at USD 284.87 and the 52-week low at USD 180.27, meaning the latest price of USD 219.52 trades roughly USD 39.25 above the 52-week low and USD 65.35 below the 52-week high, illustrating a significant recovery from the bottom but still a clear gap to the peak level.

ResMed’s market capitalization stands around USD 31.5 billion at a share price near USD 219.95, with a price-earnings ratio of about 21.1, according to valuation metrics cited by Investing.com on September 10, 2026.

Q4 FY26 fundamentals and margins

For the fourth quarter of fiscal year 2026, ResMed reported revenue of USD 1.46 billion and earnings of USD 383.43 million, corresponding to a profit margin of 26.20 percent, according to quarterly data for Q4 FY26 shown in the fundamentals section of Yahoo Finance.

The profit margin of 26.20 percent in Q4 FY26 compares favorably with many medtech peers and indicates that ResMed is converting more than a quarter of its quarterly revenue into net profit, which supports the current valuation multiple around 21.1 times earnings cited in the insider-trading analysis by Investing.com.

Over the broader fiscal year window, non-GAAP earnings per share reached USD 11.17, reflecting a 17 percent rise compared with the prior fiscal period according to an equity research article that discusses ResMed’s long-term trajectory and upside potential, as Seeking Alpha reported on September 10, 2026.

Analyst consensus and price targets

Analyst coverage currently frames ResMed as a balanced proposition: the stock carries a consensus rating of Hold and an average target price of USD 240.31, according to an analyst overview from MarketBeat on September 10, 2026.

A separate summary of price targets shows a target range between USD 175 at the low end and USD 320 at the high end, with an average target of USD 246.12 and the current price at USD 219.52, according to the analyst recommendations section of Yahoo Finance.

Within that framework, at least one analyst has recently raised the price target from USD 255 to USD 267, underscoring that some houses see upside from the recent trading level, as highlighted in the price-target change segment of the same Yahoo Finance overview dated September 10, 2026.

Risks: competition and weight-loss drug concerns

Despite strong margins and growing earnings, commentary around the sector still highlights perceived risks from weight-loss drugs potentially reducing the incidence of obstructive sleep apnea, which could weigh on demand for devices and masks over time, as discussed in a broader medtech and healthcare context by MarketBeat.

For ResMed, this perceived risk is partly offset by the company’s diversification in cloud-connected ventilation and monitoring solutions and by the demonstrated resilience of earnings growth, with non-GAAP EPS up 17 percent year over year in the latest fiscal period, according to Seeking Alpha.

Dividend and upcoming dates

ResMed offers an income component alongside growth, with a forward annual dividend of USD 2.64 per share and a dividend yield of 1.16 percent at the current price, while the most recent ex-dividend date fell on August 20, 2026, according to the dividend and yield section of Yahoo Finance.

The same data provider lists October 29, 2026 as the estimated date for the next earnings release, giving investors a time frame for the next set of quarterly figures that will show whether revenue and margins can sustain or exceed the Q4 FY26 levels reported so far, as indicated in the earnings calendar section of Yahoo Finance.

Stock level and investor perspective

At a recent price of USD 219.52 on the NYSE as of September 10, 2026, ResMed Inc. stock trades well above its 52-week low of USD 180.27 but remains notably below the 52-week high of USD 284.87, reflecting both the recovery from last year’s weakness and the market’s caution after a 3.3 percent drop in the prior session.